Mar 2, 2022 | Press Releases
Natural killer (NK) cells play a critical role in the innate immune system’s ability to combat cancer, but the key to long-term treatment effectiveness is ensuring their persistence A Washington University School of Medicine study shows that increasing NK cell...
Feb 15, 2022 | Press Releases
409,000 square foot, state-of-the-art facility expands capabilities for large-scale manufacture of vaccine and immunotherapy product candidates CULVER CITY, Calif., February 15, 2022 – ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company...
Feb 14, 2022 | Press Releases
Results confirm prolonged sustained complete response, with 71% of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) having a complete remission with a median duration of response of 24.1 months By contrast, historical...
Jan 31, 2022 | Press Releases
Data from the Phase 1 “HIV Cure” Study as published in Nature Medicine showed that Anktivaä (N-803) stimulates latent HIV replication in CD4+ cells (the kick) and increases immune cell activation (the kill) Activated CD4, CD8, and NK immune cells are necessary for...
Jan 18, 2022 | Press Releases
Data show that ImmunityBio’s combination immunotherapy, Nant Cancer Vaccine, is potentially effective in pancreatic cancer where very few treatment options exist Nant Cancer Vaccine therapy more than doubles median overall survival (OS) versus historical OS in...
Jan 12, 2022 | Press Releases
Over 400,000 square foot, state-of-the-art, finish-fill and lyophilization facility enables one billion doses of RNA and adjuvant vaccine production Newly constructed Current Good Manufacturing Practices (cGMP) facility with clean rooms will expedite capabilities for...
